DRUG-INDUCED OSTEONECROSIS OF THE JAWS
Issue:
3
Year:
2015
The paper gives an update on jaw osteonecrosis occurring with the use of different drugs.
Keywords:
osteonecrosis
phosphorus osteonecrosis
bisphosphonates
References:
- Majman G.M. Klinika i patogenez hronicheskoj fosfornoj intoksiktsii // Gor'kovskij med. zhurn. – 1934; 4–5: 81–105.
- Bruns G.F. Fosfornoe omertvenie litsevyh kostej // Vrach. – 1880; 1 (47): 772; 1 (49): 804–7; 1 (50): 829–35.
- Ruggiero S., Dodson T., Fantasia J. et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw – 2014 Update // J. Oral Maxillofac. Surg. – 2014; doi: 10.1016/j.joms.2014.04.031.
- Hillner B., Ingle J., Chlebowski R. et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer // J. Clin. Oncol. – 2003; 21: 4042.
- Saad F., Gleason D., Murray R. et al:. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma // J. Natl. Cancer Inst. – 2002; 94: 1458.
- Saad F., Gleason D., Murray R. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer // J. Natl. Cancer Inst. – 2004; 96: 879.
- Rosen L., Gordon D., Tchekmedyian N. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial // Cancer. – 2004; 100: 2613.
- Rosen L., Gordon D., Kaminski M. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial // Cancer J. – 2001; 7: 377.
- Berenson J., Hillner B., Kyle R. et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma // J. Clin. Oncol. – 2002; 20: 3719.
- Physicians' Desk Reference. 5710. th ed. Montvale / NJ: Medical Economics, 2003.
- Letocha A., Cintas H., Troendle J. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement // J. Bone Miner. Res. – 2005; 20: 977.
- Watts N. Bisphosphonate treatment of osteoporosis // Clin. Geriatr. Med. – 2003; 19: 395.
- Delmas P. The use of bisphosphonates in the treatment of osteoporosis // Curr. Opin. Rheumatol. – 2005; 17: 462.
- Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic // J. Oral Maxillofac. Surg. – 2003; 61: 1115–7.
- Ruggiero S., Mehrotra B., Rosenberg T. et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases // J. Oral Maxillofac. Surg. – 2004; 62: 527–34.
- Bagan J., Murillo J., Jimenez Y. et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases // J. Oral Pathol. Med. – 2005; 34: 120–3.
- Marx R., Sawatari Y., Fortin M. et al. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment // J. Oral Maxillofac. Surg. – 2005; 63: 1567–75.
- Durie B., Katz M., Crowley J. Osteonecrosis of the jaw and bisphosphonates // N. Engl. J. Med. – 2005; 353: 99–102
- Bennett C., Nebeker J., Lyons E. et al. The Research on Adverse Drug Events and Reports (RADAR) project // JAMA. – 2005; 293: 2131–40.
- Qi W., Tang L., He A. et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials // Int. J. Clin. Oncol. – 2013; 19 (2): doi: 10.1007/s10147-013-0561-6.
- Scagliotti G., Hirsh V., Siena S. et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study // J. Thorac. Oncol. – 2012; 7: 1823.
- Ruzin G.P., Tkachenko O.V. Kliniko-rentgenologicheskie varianty techenija osteomielita kostej litsa u narkozavisimyh bol'nyh // Ukraїns'kij stomatologіchnij al'manah. – 2013; 1: 46–50.
- Nesterov A.P., Nesterov A.A., Habibov Ja.T. Patogenez odontogennogo osteomielita cheljustej u lits s zavisimost'ju ot dezomorfina // Dental Jug. – 2012; 102 (6): 42–4.
- Barannik N.G., Varzhapetjan S.D., Mosejko A.A. i dr. Opyt lechenija patsientov s osteomielitom cheljustej i vtorichnym immunodefitsitom na fone priema narkoticheskih preparatov. Aktual'nі pitannja medichnoї nauki ta praktiki: Zb. nauk. pr. DZ «ZMAPO MOZ Ukraїni». Zaporіzhzhja. 2013; 1 (1) Vyp. 80: 12–20.
- Mostovoj S.O., Ostapenko O.V., Shul'gin V.F. Identifikatsija etiologicheskogo faktora, vyzyvajuschego «vintovye osteomility», i otsenka ego vozdejstvija na kostnuju tkan' i mochevidelitel'nuju sistemu laboratornyh belyh krys // Uchenye zapiski Tavricheskogo natsional'nogo universiteta im. V.I. Vernadskogo Serija «Biologija, himija». – 2012; 25 (64): 244–51.
- Marx R. Uncovering the cause of «phossy jaw» circa 1858 to 1906: Oral and maxillofacial surgery closed case file – Case closed // J. Oral. Maxillofac. Surg. – 2008; 66: 2356.